US 11,981,707 B2
Prefusion RSV F proteins and their use
Peter D. Kwong, Washington, DC (US); Barney S. Graham, Smyrna, GA (US); Jason S. McLellan, Austin, TX (US); Jeffrey Boyington, Clarksburg, MD (US); Lei Chen, Rockville, MD (US); Man Chen, Clarksburg, MD (US); Gwo-Yu Chuang, Rockville, MD (US); Ivelin Stefanov Georgiev, Nashville, TN (US); Jason Gorman, Silver Spring, MD (US); Michael Gordon Joyce, Washington, DC (US); Masaru Kanekiyo, North Bethesda, MD (US); Gilad Ofek, Gaithersburg, MD (US); Marie Pancera, Seattle, WA (US); Mallika Sastry, Rockville, MD (US); Cinque Soto, Rockville, MD (US); Sanjay Srivatsan, Lilburn, GA (US); Guillaume Stewart-Jones, Cambridge, MA (US); Yongping Yang, Potomac, MD (US); Baoshan Zhang, Bethesda, MD (US); and Tongqing Zhou, Boyds, MD (US)
Assigned to The United States of America, as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US)
Filed by The United States of America, as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US)
Filed on Sep. 11, 2023, as Appl. No. 18/464,786.
Application 18/464,786 is a continuation of application No. 17/478,533, filed on Sep. 17, 2021.
Application 17/478,533 is a continuation of application No. 16/025,858, filed on Jul. 2, 2018, granted, now 11,130,785, issued on Sep. 28, 2021.
Application 16/025,858 is a continuation of application No. 14/776,651, granted, now 10,017,543, issued on Jul. 10, 2018, previously published as PCT/US2014/026714, filed on Mar. 13, 2014.
Claims priority of provisional application 61/863,909, filed on Aug. 9, 2013.
Claims priority of provisional application 61/857,613, filed on Jul. 23, 2013.
Claims priority of provisional application 61/798,389, filed on Mar. 15, 2013.
Claims priority of provisional application 61/780,910, filed on Mar. 13, 2013.
Prior Publication US 2024/0018193 A1, Jan. 18, 2024
Int. Cl. C07K 14/005 (2006.01); A61K 39/12 (2006.01); A61K 39/155 (2006.01); C12N 7/00 (2006.01); G01N 33/564 (2006.01); A61K 39/00 (2006.01)
CPC C07K 14/005 (2013.01) [A61K 39/12 (2013.01); A61K 39/155 (2013.01); C12N 7/00 (2013.01); G01N 33/564 (2013.01); A61K 2039/5252 (2013.01); A61K 2039/5254 (2013.01); A61K 2039/53 (2013.01); A61K 2039/543 (2013.01); A61K 2039/55505 (2013.01); A61K 2039/55561 (2013.01); A61K 2039/55566 (2013.01); C07K 2319/21 (2013.01); C07K 2319/22 (2013.01); C07K 2319/50 (2013.01); C07K 2319/70 (2013.01); C07K 2319/735 (2013.01); C12N 2710/10343 (2013.01); C12N 2760/18522 (2013.01); C12N 2760/18534 (2013.01)] 25 Claims
 
1. An isolated immunogen, comprising a recombinant RSV F protein or an extracellular domain thereof comprising a S190I substitution that stabilizes the recombinant RSV F protein or an extracellular domain thereof in a prefusion conformation, wherein the amino acid positions of the RSV F protein are according to a reference RSV F protein sequence set forth as SEQ ID NO: 124.